Log in to your Inderes Free account to see all free content on this page.
Novo Nordisk
589.2
DKK
-20.72 %
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
213 following
-20.72%
-18.73%
-30.68%
-40.71%
-15.6%
-13.65%
+54.06%
+206.12%
+47,225.3%
Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.
Read moreMarket cap
2.63T DKK
Turnover
15.66B DKK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
5.2.
2025
Annual report '24
7.5.
2025
Interim report Q1'25
6.8.
2025
Interim report Q2'25
ShowingAll content types
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio